Life Saving

Pioneering Life-Saving Therapies

At Diverse Biotech, we are dedicated to developing innovative medications that address critical unmet needs, providing hope and solutions for patients and healthcare professionals alike.

Diverse Biotech

What Problem Are We Solving?

The pharmaceutical industry faces a critical challenge: innovation often comes from outside traditional giants. At Diverse Biotech, we are leading the charge to fill this gap, driving discovery and development in areas of greatest need.

Click and learn more

Only 10 out of 44 new products (23%) from Pfizer were discovered and developed in-house in 2020.

For Johnson & Johnson, in 2020 just 2 of their 18 leading products (11%) were internally discovered, with 81% originating from innovative companies like Diverse Biotech.

Conjugate Synthesis Platform

How Our New Drug Works Compared to Standard Therapy: Targeting Brain Cancer

Traditional approach
(The old way)
Drug 1
Drug 2

Drug 1 and Drug 2 follow separate, uncoordinated pathways, often failing to reach the same target locations.

This lack of precision—combined with widespread toxicity—leads to harmful effects throughout the body and limits therapeutic success.

New conjugate approach
(The New Way)
Drug 1 +2
CBD

With our innovative conjugate technology, Drug 2 is released precisely at the site of Drug 1’s action, ensuring both are always present at the same location.

This targeted delivery dramatically reduces toxicity compared to Drug 1 and Drug 2 alone. The toxic effects are localized to the site of the cancer, sparing the rest of the body from harmful side effects.

The New Way

Specific Advantages of Conjugate Platform

Click and learn more

Step Increase in Efficacy

  • Rapid absorption and distribution
  • Increased lipophilicity (enabling crossing of the blood–brain barrier)
  • Effectiveness exceeding 10x the current standard of care
  • Potential to lower doses of current highly toxic therapeutic agents on the market

Improved tolerability for patients

  • Decreased toxicity
  • Fewer side effects

Multiple Functionality

  • Patented across various drug families and classes in multiple disease states
  • Patent extensions on existing drugs
  • Significantly de-risks drug discovery by leveraging well-studied entities

Our Inventors

Pioneering Science | A Proven Track Record of Success

Paul Hershberger, PhD

Chief Chemist

Philip Arlen, PhD

Chief Scientific Officer

Our Discovery

Diverse Biotech Innovation & Medical Discovery

Diverse Biotech, Inc., is not a “single-drug” or “single-disease” company.

Learn More